Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > RLYB Rallybio > Detailed Quotes

RLYB Rallybio

Watchlist
10.760
-4.100-27.59%
Close 10/04 16:00 ET
10.76000.00%
Post Mkt Price 10/04 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
14.550
Open
14.290
Turnover
1.75M
Low
10.120
Pre Close
14.860
Volume
150.13K
Market Cap
345.74M
P/E(TTM)
Loss
52wk High
21.000
Shares
32.13M
P/E(Static)
Loss
52wk Low
5.900
Float Cap
108.67M
Bid/Ask %
66.67%
Historical High
25.780
Shs Float
10.10M
Volume Ratio
2.70
Historical Low
5.900
Dividend TTM
--
Div Yield TTM
--
P/B
2.34
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.49%
Amplitude
29.81%
Avg Price
11.632
Lot Size
1
Float Cap
108.67M
Bid/Ask %
66.67%
Historical High
25.780
Shs Float
10.10M
Volume Ratio
2.70
Historical Low
5.900
Dividend TTM
--
P/B
2.34
Dividend LFY
--
Turnover Ratio
1.49%
Amplitude
29.81%
Avg Price
11.632
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
CEO: MacKay Ph.D., Martin W.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top